Side effects in the treatment of XXXX .

@entity1 @entity1033 @entity12948 @entity1034 @entity2372 @entity566 @entity5526 @entity41463 @entity3897 @entity2024 @entity43592 @entity73237 @entity28299
Various side effects due to antiherpetic drugs observed in the last ten years in our department were studied. A total of 132 @entity1 were treated with @entity41463 ( @entity28299 ), 69 with @entity43592 ( @entity73237 ), 58 with @entity1033 (ACV) and 33 with @entity12948 (ara-A). Patch tests were routinely done when @entity1 exhibited @entity5526 . Of the @entity1 treated with @entity28299 , 3 (2.3%) showed @entity5526 , 2 (1.5%) @entity2024 and 1 (0.8%) @entity2372 . Of the @entity1 treated with F3T, 7 (10.1%) exhibited @entity5526 and 1 (1.4%) @entity2024 . In the group treated with ACV, 2 (3.4%) @entity1 showed @entity2372 . The @entity1 who received ara-A did not show any side effects. We found that F3T caused @entity5526 more frequently in Japanese @entity1 than Europeans. These side effects were resolved by switching to another anti-herpetic drug without the occurrence of cross- @entity566 . Therefore, switching to another drug is strongly recommended when @entity1 exhibit side effects in the treatment of @entity1034 . Other complications were @entity566 to @entity3897 and to drug preservative.
